Live Event: In Silico Deep Dive, Clinical Trials, OSA Treatment, and Modern Medicine | Simq Pulse #7

Live Event: In Silico Deep Dive, Clinical Trials, OSA Treatment, and Modern Medicine | Simq Pulse #7

This newsletter introduces you to a world of possibilities that can transform patient care, exploring the frontiers of innovation and technology!

Here’s what you can expect:

  • Valuable Insights: Discover valuable insights garnered from our pioneering journey in the field of in silico medicine!
  • Latest Updates: Dive into the latest trends, technologies, and up-to-date information in the continuously evolving medical landscape.
  • Educational Resources: Access informative content designed to expand your knowledge and understanding.

Follow us for a continuous stream of insights and discoveries!


Live Event Recap- In Silico Deep Dive

The deep dive event ‘Finite Element Analysis In Medicine’ went live on Tue May 7th, 11 AM CEST.

In this live session, we talked about In silico medicine and dental simulation workflows with Jousef Murad .

??Some of the questions discussed are:

- What is in silico? - How does Simq take advantage of modern simulations to produce high-quality dental workflows? - How advanced and precise are our simulations?

Didn’t catch us? No worries!

?? Watch the deep dive here .


Simq - Supporting You In Every Step

Simq offers you support at every stage in the life cycle of your medical device.

Simq’s simulations are your pillars of support!

Whether during the research and development phase, the approval process, or in your post-market surveillance, our services offer you help all the way from start to end!

??? Book a free consultation today: https://simq.de/en/services/


Developing In-Silico Clinical Trials

Virtual simulation improves safety and outcomes for patients.

Clinical studies provide us with knowledge to inform clinical and regulatory practice. Mark Palmer from Ansys joined us at the Simq conference to discuss how healthcare today does not have a safety requirement of screening with human simulations first in the clinical stage for bringing a new product to the market. Instead, safety is evaluated by endpoints in these stages of human testing that expose the patient to morbidity and mortality.

In silico clinical trials have the potential to improve the process of clinical trials as they are carried out today. The impact of in silico clinical trials includes a reduced number of patients, reduced cost of trials, and reduced time to market. By incorporating this new technology into today’s medicine, we can save on costs while enhancing the safety of thousands of patients in these studies. The process from in vitro research to product release is long and complex.

?? Learn more about the potential of in silico methods in the stage of clinical trials by watching the conference here: https://www.youtube.com/watch?v=_VyeNEbSyvU


Advancing Obstructive Sleep Apnea Treatment | Simq OSA ???

Simq OSA helps clinicians identify anatomical causes of OSA.


A recently published review article highlights the heterogeneity among individuals with obstructive sleep apnea (OSA) and the varied treatment responses observed. The authors, from Yale school of medicine, discuss how anatomical and physiological factors contributing to OSA can influence treatment outcomes. These traits include anatomical factors such as upper-airway collapsibility, and physiological factors such as loop gain, airway muscle responsiveness, and arousal threshold. Furthermore, it is suggested that identifying these OSA factors before initiating treatment could aid in selecting the most effective and tolerable therapy modalities for each individual.

At Simq, we have developed Simq OSA, a software product that utilizes virtual simulation to assess OSA, a new technology that could play a crucial role in identifying these physiological factors. Simq OSA uses efficient flow simulations of a patient-specific airway to enable the localization of anatomical causes. By using these simulations, Simq OSA helps clinicians pinpoint specific OSA factors in individual patients. This information can then guide the selection of appropriate treatment modalities, ensuring more personalized and effective care for patients with OSA.

?? Read the full article here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10970765/


Simq & Ansys At the Forefront of Modern Medicine ??

Are you interested in learning more about the shift towards personalized medicine and how technology, particularly simulation tools like Simq's, is driving this change?

Ansys highlights the role of Simq’s simulation products in the growing field of personalized medicine.


?? Ansys ’ recent blog post highlights the inefficiencies of the current one-size-fits-all approach in healthcare and emphasizes the potential of personalized treatment plans tailored to individual patients. Simq's applications, such as Simq VIT, Simq OSP, and Simq OSA, are introduced as solutions to democratize simulation in the medical field.?

You will also learn about the regulatory challenges faced by companies like Simq and how compliance is navigated to ensure that software meets safety standards.?

Learn how Simq is making it easier for medical device manufacturers to navigate complex standards and bring innovative solutions to market faster!

?? Read the full blog post here .


To continue your exploration of AI medical technologies, Digital Twins, and innovative healthcare solutions, consider subscribing to this newsletter!

Stay Informed. Stay ahead.

Jan Hertwig

要查看或添加评论,请登录

社区洞察

其他会员也浏览了